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Introduction: There is limited data on mortality and associated morbidity in non-cystic fibrosis
bronchiectasis (NCFB). Our aim was to analyze the overall mortality for all newly diagnosed
patients from June 2006 onwards and to evaluate risk factors for mortality in this cohort.
Methods: 245 patients who had a new diagnosis of NCFB between June 2006 and October 2012
at the University Hospital of Leuven, Belgium, were included in the analysis. Death was
analyzed until end of November 2013. All patients had chest HRCT scan confirming the pres-
ence of bronchiectatic lesions and had symptoms of chronic productive cough. Univariate
and multivariate Cox proportional hazard survival regression analysis was used to estimate haz-
ard ratios (HR) and their 95% confidence intervals (CI) of variables possibly predicting mortal-
ity.
Results: Overall mortality in NCFB patients who had a median follow-up of 5.18 years was
20.4%. Patients with NCFB and associated chronic obstructive pulmonary disease (COPD) had
a mortality of 55% in that period. Univariate analysis showed higher mortality according to
age, gender, smoking history, Pseudomonas aeruginosa status, spirometry, radiological extent,
total number of sputum bacteria and underlying etiology. Multivariate analysis showed signif-
icant higher mortality with increasing age (HRZ 1.045; pZ 0.004), with increasing number of
lobes affected (HR Z 1.53; p Z 0.009) and when patients had COPD associated NCFB
(HRZ 2.12; pZ 0.038). The majority of the 50 deaths were respiratory related (nZ 29; 58%).ere presented in an oral presentation at the American Thoracic Society congress 2013 Philadelphia.
ospital Gasthuisberg, Department of Lung Disease, Herestraat 49, B-3000 Leuven, Belgium. Tel.: þ32
student.kuleuven.be (P.C. Goeminne).
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288 P.C. Goeminne et al.Conclusion: NCFB patients with associated COPD disease had the highest mortality rates
compared to the other NCFB patients. Additional risk factors for lower survival were increasing
age and number of lobes affected.
ª 2014 Elsevier Ltd. All rights reserved.Background
Bronchiectasis is defined as permanently dilated airways
due to chronic bronchial inflammation caused by inappro-
priate clearance of various microorganisms and recurrent or
chronic infection [1]. With the exception of cystic fibrosis
(CF), there is a lack of research into bronchiectasis.
Recently, De Soyza et al. proposed several research prior-
ities in non-cystic fibrosis bronchiectasis (NCFB). They state
that from an epidemiological point of view, more pro-
spective data are needed on mortality and associated
morbidity [2].
Several retrospective analyses have already been per-
formed. In England and Wales, just under 1000 people die
from bronchiectasis with the number increasing 3% per
year [3]. In a hospital setting, mainly older age (>65
years), male gender, smoking history, mechanical venti-
lation, socioeconomic status (SES) and lower lung function
show higher mortality [4e7]. In a cross-sectional retro-
spective analysis of patients known with a radiological
diagnosis of bronchiectasis (including asymptomatic
interstitial lung disease and thoracic tumor patients), we
previously showed a 41-month death rate of 10.6% [8].
These data are in line with the long term prospective
analysis by Loebinger et al. They found that over a 13-
year period, 29.7% of the 91 patients died, and male
gender, older age, lung function and Pseudomonas aeru-
ginosa (PA) were correlated with higher mortality [9].
Another prospective analysis from Turkey showed an even
poorer outcome with 4-year survival of only 58%. They
suggest that the presence of hypoxemia, hypercapnia,
dyspnea levels and radiographic extent lead to higher
mortality [10].
Our primary aim was to analyze the overall mortality for
all newly diagnosed patients from June 2006 onwards. We
assessed the known risk factors such as age, gender,
smoking history, number of lobes affected, type of bron-
chiectasis and PA and evaluated the impact on mortality of
etiology, number of different bacteriological species in
retrospective and prospective sputa, azithromycin and
other long-term antibiotic use and presence/development
of pulmonary hypertension (PH).Materials and methods
Patient selection
Patients who had a new diagnosis of bronchiectasis be-
tween June 2006 and October 2012 at the University Hos-
pital of Leuven, Belgium, were included in the analysis.
Death was analyzed until end of November 2013. Patients
with clinically significant and radiologically proven bron-
chiectasis were included in the analysis.Bronchiectasis diagnosis
All patients had a chest high resolution computed tomog-
raphy (HRCT) scan confirming the presence of bron-
chiectatic lesions and had symptoms of chronic productive
cough. HRCT scans were evaluated by two experienced in-
dependent radiologists. Images obtained using 1 mm colli-
mation at full inspiration were reviewed and bronchiectasis
was deemed to be present if there was one or more of the
following criteria: a bronchoarterial ratio greater than 1,
lack of tapering of the bronchi and visualization of bronchi
within 1 cm of costal or paravertebral pleura or abutting
the mediastinal pleura [11]. Exclusion criteria were pa-
tients with a diagnosis of CF (CF transmembrane regulator
sequences present on genotyping), an underlying tumoral
problem causing the bronchiectatic lesions (post-radiation,
secondary immunodeficiency due to chemotherapy or
postinfectious due to tumoral obstruction) and patients
with traction bronchiectasis caused by interstitial lung
disease or sarcoidosis. Each patient with a diagnosis of
NCFB was further evaluated for an underlying cause with
serum protein electrophoresis, immunoglobulines (IgA, IgE,
IgM, IgG, IgG1-3), specific IgE to Aspergillus fumigatus,
specific IgG to A. fumigatus, nasal NO measurement,
sputum microbiology and ororhinolaryngological evalua-
tion. Spirometry and plethysmography were performed to
evaluate impact on lung function. Additional investigations
were guided by clinical indication. Postinfectious NCFB was
defined as NCFB where there is a clear medical history of a
respiratory infection with a distinct isolated pathogen that
meant the start of the chronic respiratory complaints or
(when no such pathogen could be isolated), a history of
recurrent childhood respiratory infections that meant the
start of the chronic respiratory complaints. If patients with
a primary diagnosis of idiopathic NCFB also had concomi-
tant COPD, they were categorized in the COPD associated
NCFB group. COPD was defined using the definition sug-
gested by the Global Initiative for Chronic Obstructive Lung
Disease (GOLD). More precisely, patients needed to have
symptoms of shortness of breath, chronic cough or sputum
production, and a history of exposure to smoke. Patients
also needed persistent airflow limitation defined as the
presence of a post-bronchodilator FEV1/FVC ratio lower
than 0.7 (www.goldcopd.org). The initial diagnosis of COPD
was made by the general practitioner, the referring respi-
ratory physician or by the outpatient clinic of COPD at the
University Hospital of Leuven.
Data collection
The following patient data were collected at inclusion: age,
gender, smoking habits (four categories: active, former,
passive or never smoker), PA infection status according to
the criteria defined by Lee et al. [12], total number of
Mortality in non-cystic fibrosis bronchiectasis 289different bacterial species in retrospective and prospective
sputa, presence of PH (defined as a systolic pulmonary
arterial pressure of 36 mmHg on echocardiography
assuming normal right atrial pressure of 5 mmHg) [13],
exacerbation rate (defined as the use of antibiotic treat-
ment due to two or more of the following symptoms: in-
crease in sputum volume, increase of sputum purulence,
dyspnea, cough, hemoptysis or fever more than 38 C),
azithromycin use (a minimum dose of 250 mg three times a
week during at least 3 consecutive months), other long-
term antibiotic use (antibiotic treatment longer than 3
months), SES (based on education level and/or occupation
of the head of household and divided by low, middle or high
status), spirometry (according to the ATS/ERS guidelines
[14,15]), number of lobes affected and type of bronchiec-
tasis (based on the worst type present on HRCT: cylindrical,
varicous or cystic). For all patients, sputum culture results,
therapy use and death were assessed each six months. If
death occurred, the patient file was reassessed to identify
cause of death mentioned in the patient file.
Ethical committee
Approval was obtained from the local ethical committee of
UZ Leuven, Belgium (B51060 e B32220084152) and was
registered at ClinicalTrial.gov (NCT01792427).
Statistics
Data were expressed as mean with standard deviation (SD)
or median with 25%e75% interquartile range (IQR) based on
the distribution of the data. For percent survival and pre-
sentation of the figures on total mortality and etiology
mortality subanalysis, a KaplaneMeier analysis was per-
formed with a log-rank test to compared different etiology
subgroups and the curves presented using GraphPad Prism
5. For the univariate mortality analysis, Cox proportional
hazard regression analysis was used to estimate hazard
ratios (HR) and their 95% confidence intervals (CI) of several
parameters possibly predicting NCFB mortality. For multi-
variate analysis of factors associated with mortality, a
multivariate Cox regression analysis was performed. Vari-
ables that were significant in the univariate model were
included in the multivariate analysis. Analysis was per-
formed using SAS 9.3 and GraphPad Prism 5. P-values were
considered to be significant if lower than 0.05 and two-
tailed testing was performed.
Results
Patient characteristics
In total 245 patients with a median follow-up of 5.18 years
(IQR 4.17e6.38) were included. Patient characteristics are
shown in Table 1.
Univariate mortality analysis
Overall mortality in NCFB patients who had a median follow-
up of 5.18 years was 20.4% (50 deaths, 195 survivors; Fig. 1).Etiology subanalysis showed significant differences between
the different causes (Fig. 2). Patients with bronchiectasis
who had associated chronic obstructive pulmonary disease
(COPD) had the worst outcome of all NCFB patients. During
the median follow-up of 5.18 years, 55% of the COPD asso-
ciated NCFB died. Over the median 5.18-year follow-up, 14%
of the patients with idiopathic NCFB and 16% of the post-
infectious NCFB died. In the miscellaneous group 12% died
over the follow-up period. This group includes anatomic
malformations, immunodeficiencies, rheumatic disease,
primary ciliary dyskinesia (PCD), allergic bronchopulmonary
aspergillosis (ABPA), a1-antitrypsin deficiency, vasculitis and
inflammatory bowel disease. For the larger subgroups in the
miscellaneous group (rheumatic disease, ABPA and immu-
nodeficiency), we found that 20% of the patients with rheu-
matic disease, 11% of the patients with an underlying
immunodeficiency and 13% of the ABPA NCFB patients died
over the median follow-up period of 5.18 years.
Subanalysis showed significantly different mortality
curves in patients with different age, gender, smoking
habits, chronic PA colonization (PACC) status (using the
criteria defined by Lee et al.) [12], increased total number
of different bacterial species in all collected sputa, spiro-
metric values, radiological severity and extent of disease
(Table 2). A trend was seen for SES, PH and long-term
antibiotic use but no significance for exacerbation rate
(Table 2). When we accounted for the duration of azi-
thromycin use, results remained not significant (pZ 0.97).Multivariate analysis
Multivariate Cox regression analysis could identify three
significant factors associatedwith highermortality (Table 3).
Age was associated with a higher mortality (HRZ 1.045; 95%
CI 1.01e1.08;pZ0.004)with aparameter estimateof 0.044.
Increasing number of lobes affected were also significantly
associated with mortality (HR Z 1.53; 95% CI 1.11e2.09;
p Z 0.009) with a parameter estimate of 0.42. A third sig-
nificant factor for higher mortality in the multivariate anal-
ysis was the presence of COPD associated NCFB (HRZ 2.12;
95%CI 1.04-4.30; pZ 0.038) as compared to other etiologies,
even when omitting spirometric values from the analysis (as
they might interact with COPD) (HR Z 2.20; 95% CI
1.15e4.21; pZ 0.017). Finally, a trend was seen when never
smokerswere compared to active smokers (HRZ 2.55; 95%CI
0.96e6.79; pZ 0.06).Causes of death
The majority of deaths were respiratory related (58%;
n Z 29; respiratory failure, most frequently due to respi-
ratory infection) or cardiovascular (16%; n Z 8; acute
myocardial infarction, rupturing aneurysm, arrhythmia,
cardiac failure). For some patients (12%; n Z 6) no clear
cause of death was noted in the clinical records. Other
causes were neurological (4%; nZ 2; craniocerebral trauma
and stroke), gastrointestinal (2%; nZ 1; pancreatic tumor),
nephrological (2%; n Z 1; acute kidney failure), haemato-
logical (2%; n Z 1; leukemia), euthanasia (2%; n Z 1) and
intoxication (2%; n Z 1; alcohol).
Table 1 Patient characteristics: For socio-economic status (nZ 189) and PH (nZ 117) we did not have data from all patients.
Data are expressed as median with IQR or mean with standard deviation. All antibiotic treatment was given for at least 3
months. Colistimethate was inhaled. The bacteria isolated in sputa mentioned in the table are the most relevant bacteria with a
prevalence of more than 5%. The postinfectious causes were tuberculosis (n Z 23), childhood recurrent infections without a
clear pathogen (nZ 18), Mycobacterium avium complex (nZ 3), invasive aspergillosis (nZ 2), HIV (nZ 1), childhood measles
pneumonia (n Z 1) and severe childhood diphtheria (n Z 1). The ‘miscellanous’ group includes a1-antitrypsin deficiency
(n Z 2), vasculitis (n Z 3), inflammatory bowel disease (n Z 5), anatomic malformations (n Z 3), PCD (n Z 8), rheumatic
disease (n Z 25), immunodeficient (n Z 18) and ABPA (n Z 15). ABPA Z Allergic Broncho-Pulmonary Aspergillosis;
COPD Z chronic obstructive pulmonary disease; F Z Female; FEV1 Z Forced Expiratory Volume in one second; FVC Z Forced
Vital Capacity; IQR Z Interquartile range; M Z Male; NCFB Z Non-cystic fibrosis bronchiectasis; PCD Z Primary Ciliary Dis-
kinesia; PH Z Pulmonary Hypertension; TMP/SMX Z trimethoprim/sulfamethoxazole. Pseudomonas aeruginosa status was
categorized according to the criteria by Lee et al. [12].
Gender M/F 49%/51%
Median age (years) 68 (IQR 56e78)
Total n of different bacterial species
in retrospective sputa
1 (IQR 0e2)
Number of exacerbations 1 (IQR 0e3)/year
Smoking history Never smokers 48.9%
Former smokers 30.3%
Passive smokers 3.2%
Active smokers 17.6%
Socio-economic status (n Z 189) Low 52.9%
Middle 42.3%
High 4.8%
PH in echocardiography (n Z 117) 45.3%
Etiology Idiopathic 32%
Postinfectious 20%
Miscellanous 31%
COPD associated NCFB 17%
Pseudomonas aeruginosa status Never 78.8%
Free 9.4%
Intermittent 3.6%
Chronic 8.2%
n of lobes affected One lobe 17.1%
Two lobes 25.3%
Three lobes 24.9%
Four lobes 16.8%
Five lobes 15.9%
Type of bronchiectatic lesion Cilyndrical 62%
Varicous 30%
Cystic 8%
FEV1% 70%  27%
FVC% 87%  25%
Bacteria isolated in sputa
- Haemophilus influenzae
- Streptococcus pneumonia
-Staphylococcus aureus
- Aspergillus spp.
- Moraxella catarrhalis
- Stenotrophomonas maltophilia
18.8%
14.6%
13.5%
11.4%
7.8%
6.9%
Long-term antibiotic use
- Azithromycin use
- Other
38%
clarithromycin (n Z 10),
itraconazole (n Z 7),
voriconazole (n Z 2),
colistimethate (n Z 6),
rifampicin (n Z 5),
pyrazinamide (n Z 2),
290 P.C. Goeminne et al.
Table 1 (continued )
ethambutol (n Z 7),
TMP/SMX (n Z 5),
amoxicillin clavulanate (n Z 1),
moxifloxacin (n Z 4),
isoniazid (n Z 5)
Mortality in non-cystic fibrosis bronchiectasis 291Discussion
Our results show that during the analyzed period, 20.4% of
the patients died, with more deaths amongst NCFB patients
with associated COPD. The majority of deaths were due to
respiratory failure. Univariate analysis showed higher
mortality according to age, gender, smoking history, PA
status, spirometry, radiological extent/severity, total
number of sputum bacteria and underlying etiology. Multi-
variate analysis resulted in the following risk factors asso-
ciated with higher mortality: age, number of lobes affected
and COPD associated NCFB.
Our analysis with a median follow-up of 5.18 years
showed a mortality of 20.4%. These percentages are in line
with our previous cross-sectional retrospective analysis
and slightly higher than results from the prospective
analysis by Loebinger et al. where the 4-year mortality
was 9% and the 8.8-year mortality 16.5% [9]. However, the
population studied by Loebinger and colleagues shows a
low prevalence of COPD as 77% were never-smokers and
less than 4% had emphysema on HRCT [9]. When we
analyze the survival curves of the idiopathic, post-
infectious and other etiologies, we can perceive that
these are in line with the data of Loebinger et al. Mortality
of our NCFB patients (even the best performing etiological
subgroups) is still higher than the general population in
Belgium, where a mortality of 9.66& and 9.51& was seenFigure 1 KaplaneMeier survival curve of the NCFB cohort
over the study period: a mortality of 20.4% was seen over a
median follow-up time of 5.18 years.in 2006 and 2007 respectively [16]. We speculate that the
vicious cycle of inflammation, infection and structural
damage with inappropriate mucus clearance increases the
chances that an infection can lead up to severe respiratory
insufficiency as compared to the general population,
causing excess mortality.
The higher mortality in older, male and smoking patients
was previously acknowledged by several authors [4e7,9].
One possible explanation is the fact that the COPD patients
were predominantly male. We also found that active and
ex-smokers were predominantly male whereas never
smokers were predominantly female. After multivariate
correction, age was still significant a factor associated with
higher mortality. Apart from the logic increase in mortality
with increasing age, another contributing factor might be
the overall lower compliance in older patients [17,18].
Whether closer follow-up or better patient education might
improve compliance and therefore decrease mortality re-
quires further research.
Loebinger et al. could not assess differences in mortality
rates among the different etiologies as the numbers in the
several subgroups were too small [9]. Our larger group
allowed subanalysis, showing higher mortality rates for
patients with associated COPD, even after multivariate
analysis. Whether COPD associated bronchiectasis is a
distinct COPD phenotype, cannot be concluded from our
study as we did not compare COPD patients without bron-
chiectasis. However, our data add to previous research
suggesting that COPD with bronchiectasis is different fromFigure 2 KaplaneMeier log-rank test survival curve per NCFB
etiology over the study period: There was a median follow-up
time of 5.18 years and the study period started in June 2006
and ended in November 2013. COPD Z Chronic Obstructive
Pulmonary Disease; NCFBZ Non-cystic fibrosis bronchiectasis.
Table 2 Univariate analysis of factors associated with survival: For socio-economic status (nZ 189) and PH (nZ 117) we did
not have data from all patients. For non-continuous data, we displayed the classes how they were analyzed. Therefore the
hazard ratio reflects the increase for each class increase. M/H Z Middle/High; n Z number; V/C Z Varicous/Cystic;
vs Z versus.
Hazard ratio 95% Confidence interval Number of patients
dead versus alive
p-Value
Age (years) 1.06 1.04e1.09 NA p < 0.0001
Gender
Female vs Male
4.16 2.13e8.13 Female
Male
11/124
39/121
p < 0.0001
Smoking
Never vs Passive vs Ex vs Active
1.61 1.27e2.05 Non
Passive
Ex
Active
12/120
2/8
21/74
15/43
p < 0.0001
Socio-economic status
Low vs Middle/High
0.59 0.30e1.14 Low
M/H
Unknown
24/100
14/89
12/56
p Z 0.11
Pulmonary hypertension
Absence vs presence
1.59 0.87e2.90 Absent
Present
Unknown
19/64
24/53
7/128
p Z 0.13
Pseudomonas aeruginosa status
Never vs free vs intermittent
vs chronic
1.60 1.27e2.00 Never
Free
Intermittent
Chronic
29/193
8/23
3/9
10/20
p < 0.0001
FEV1 (%) 0.97 0.96e0.99 NA p < 0.0001
FVC (%) 0.98 0.97e0.99 NA p Z 0.001
n of exacerbations/year 1.01 0.88e1.15 NA p Z 0.94
n of different bacteria in sputum 1.38 1.23e1.54 NA p < 0.0001
Type
Cylindrical vs varicous/cystic
2.55 1.46e4.48 Cylindrical
V/C
21/153
29/92
p Z 0.001
n of lobes affected 1.95 1.54e2.48 One
Two
Three
Four
Five
0/42
6/62
12/61
13/41
19/39
p < 0.0001
Long-term azithromycin use 0.61 0.33e1.13 Yes
No
14/152
36/93
p Z 0.11
Long-term antibiotic treatment 0.54 0.29e1.00 Yes
No
14/146
36/99
p Z 0.0513
292 P.C. Goeminne et al.bronchiectasis in other circumstances [19e21]. The higher
mortality might be attributed to the fact that these pa-
tients have more severe and more frequent exacerbations,
higher degree of airway inflammation, lower lung function
and increased colonization [19,22,23]. It is also possible
that the diagnosis of bronchiectasis is delayed in NCFB
patients with COPD as the COPD itself can explain the
majority of their symptoms. Many less severe COPD pa-
tients will be managed in the community but still may have
bronchiectasis and COPD [22]. Recent work by Martinez-
Garcia and colleagues evaluated the impact of bronchiec-
tasis on COPD, approaching this problem from a COPD
population perspective. They clearly show that bronchi-
ectasis was associated with an independent risk of all-
cause mortality in patients with COPD. In their analysis,
COPD alone had a mortality of 9.3% whereas our NCFB
patients without concomitant COPD had a mortality of
13.3%. More importantly, the combination of COPD and
NCFB had similar high mortality rates as our data with a
death rate of 37.8% in their study and 55% in our analysis.This suggests that it is not the NCFB or the COPD alone that
causes excess mortality, but the combination of both [24].
These high mortality rates and the diagnostic delay often
seen in NCFB with concomitant COPD imply that COPD
patients with symptoms suggestive of bronchiectasis, such
as frequent infectious exacerbations or chronic mucopur-
ulent/purulent expectorations, need further investigation
via HRCT.
Multivariate analysis also underlined that the extent of
the disease is a risk factor for higher mortality. Extent of
the bronchiectasis was a very significant factor in the paper
by Loebinger and colleagues but they did not assess HRCT
scored in a multivariate way [9].
NCFB patients with an underlying rheumatological dis-
ease also had a high mortality of 20% as opposed to most
other NCFB etiologies, with the exception of COPD associ-
ated NCFB. Swinson et al. previously found that the pres-
ence of bronchiectasis in rheumatological disease may be
clinically relevant. Patients with rheumatological disease
and bronchiectasis were 7.3 times more likely to die during
Table 3 Multivariate Cox regression analysis of factors associated with survival: Significant factors associated with higher
mortality in the multivariate analysis are age, number of lobes affected and COPD associated non-cystic fibrosis bronchiectasis.
A trend towards significance was seen for active smokers. To account for the interaction between spirometry and COPD we
performed both multivariate analyses with and without spirometric data. COPD Z Chronic Obstructive Pulmonary Disease;
FEV1 Z Forced Expiratory Volume in one second; FVC Z Forced Vital Capacity; vs Z versus; NCFB Z Non-Cystic-Fibrosis
Bronchiectasis; n Z Number.
Multivariate cox regression variable Hazard ratio for death 95% Confidence interval p-Value
Age (years) 1.045 1.01e1.08 p Z 0.004
Gender
Male vs female
1.75 0.70e4.35 p Z 0.23
Smoking
Ex vs never
Passive vs never
Active vs never
1.04
3.25
2.55
0.40e2.68
0.63e16.87
0.96e6.79
p Z 0.94
p Z 0.16
p Z 0.06
Pseudomonas aeruginosa status
Chronic colonization vs non-chronic
1.35 0.61e2.97 p Z 0.46
Total different bacterial species in all sputa 1.10 0.96e1.25 p Z 0.18
Type
Varicous/cystic vs cylindrical
1.44 0.69e2.98 p Z 0.33
n of lobes affected 1.53 1.11e2.09 p Z 0.009
FEV1 (%) 0.99 0.97e1.01 p Z 0.41
FVC (%) 1.01 0.99e1.03 p Z 0.46
Etiology
COPD associated NCFB vs other
2.12 1.04e-4.30 p Z 0.038
Multivariate cox regression without FEV1 and FVC Hazard ratio for death 95% confidence interval p-Value
Etiology
COPD associated NCFB vs other
2.20 1.15e4.21 p Z 0.017
Mortality in non-cystic fibrosis bronchiectasis 293a 5-year follow-up period than the general population, five
times more likely to die than those with rheumatological
disease alone and 2.4 times more likely to die than those
with bronchiectasis alone [25]. One explanation may be the
increased risk for respiratory infections associated with
immunomodulatory therapy [26,27]. Another explanation
might be the lower FEV1 in coexisting NCFB and rheuma-
tological disease as opposed to other NCFB patients [25].
This is in line with our previous data, suggesting that
rheumatological disease severity scores inversely correlate
with lung functional parameters [26].
The lack of association between mortality and SES in the
univariate analysis is somewhat hampered by the lack of
data. We only had sufficient SES data from 196 patients.
There is however a trend towards significance comparing
low to middle class status. This is in line with bronchiectasis
data from New Zealand, showing that socio-economic
deprivation had a negative impact on survival [6].
We further found a higher mortality in patients with
PACC and in patients with number of different bacterio-
logical species present in sputum in the univariate analysis.
We know from literature that PA infection is more prevalent
in patients with more severe bronchiectatic disease and
causes lower quality of life and worse lung function [27,28].
PACC is linked with accelerated decline in lung function,
more severe exacerbations and higher systemic inflamma-
tion [29,30]. Although PACC was not significant in our
multivariate model (possibly due to an overadjusted
model), PA infection and PACC are important in NCFB. Our
univariate analysis showed a parameter estimate of 0.47 foreach increase in Pseudomonas colonization class using the
criteria of Lee et al. [12] The importance of PACC was
recently confirmed by Martı´nez-Garcı´a and colleagues,
using PACC as an element of their bronchiectasis FACED
severity score [31]. This was simultaneously confirmed by
Chalmers et al. in their Bronchiectasis Severity Index [32].
It is therefore important to stay vigilant for the appearance
of PA in sputa using regular sputum cultures and timely
eradication. It is not clear if first acquisition of PA in NCFB is
different from CF, but recent research by De Soyza and
colleagues suggests that (in contrast to CF) cross-infection
is rare in NCFB patients [33].
Recently, two scoring systems were published addressing
the severity of bronchiectasis. The FACED score is an easy
tool that scores 7 points using 5 dichotomized variables to
predict mortality and includes FEV1, age, PACC, number of
lobes affected and shortness of breath [31]. The Bronchi-
ectasis Severity Index predicts both the chance of future
hospitalization and mortality and has been validated in
other centers around Europe. For mortality they found that
older age, lower FEV1, prior hospitalization and three or
more exacerbations were of significant importance [32].
Both models show that the majority of the factors we found
in our univariate analysis play a role in predicting mortality
and they are excellent tools to use in daily clinical practice.
However, both studies did not investigate the importance
of the underlying etiology or associated conditions into
their model. We add that associated COPD might play a
pivotal role in predicting mortality, but further research
with larger populations is needed.
294 P.C. Goeminne et al.Although PH is a known risk factor for mortality and the
percentages of deaths were higher in the patients with PH
(42%) versus without PH (28%), there was no significant
difference in terms of mortality [34]. This might be
hampered by the lack of echocardiographic data in 130
patients. Not only has research shown a high prevalence of
PH in COPD patients [35,36], but PH is also known to be of
importance in NCFB as right ventricular dysfunction and
right ventricular dimensions are greater in cystic NCFB and
are positively correlated with systolic pulmonary artery
pressure and negatively correlated with partial pressure of
oxygen in arterial blood. In more severe NCFB, there is an
impaired perfusion with more capillary bed destruction and
left-to-right shunt, leading to impaired cardiac function
and pulmonary gas exchange [37].
There was no significant difference in mortality whether
NCFB patients were taking azithromycin or not. To our
knowledge, the effect of azithromycin on mortality has not
been assessed previously. An improvement of exacerbation
rate, HRCT score and lung function were observed in
retrospective studies [38,39], which was recently confirmed
by several double-blind, placebo-controlled trials [40,41].
The low number of patients, duration of therapy and lack of
a control population in our study limits this subanalysis.
More research is needed to establish the effect of azi-
thromycin on mortality in NCFB.
Although women are usually predominant in NCFB series,
we saw an equal distribution between men and women.
This equal distribution is caused by the predominantly male
COPD group, whereas the idiopathic and postinfectious
bronchiectasis were predominantly female.
One limitation of our study might be the overadjusted
multivariate model as we included all univariate significant
results in the multivariate model, adding ten variables to
the model having only 50 events. To analyze stability of the
significant and non-significant variables, we have omitted
certain variables in a second analysis (data not shown). The
omission of spirometric values (as they might have an
interaction with COPD) and number of bacteria in sputum,
showed no change in significance of the variables in the
multivariate Cox regression model and little change in HR
of the variables. Nonetheless, overadjustment is possible
and might underestimate the number of multivariate sig-
nificant variables.
Another limitation is the absence of a severe respiratory
condition in a large percentage of our population, given the
rather low number of exacerbations and an overall good
lung function. This might account for the absence of
multivariate significance of PACC, number of exacerbations
and FEV1 in the mortality analysis, whereas other groups
have found these factors to be of significant importance
[31,32]. Another reason for the absence of PACC in the
multivariate analysis is the significant association we found
between number of lobes and PA status (data not shown).
A third limitation might be the fact that some of the
patients needed long-term antibiotic treatment for
several reasons (treatment for ABPA, Aspergillus or (non)-
tuberculous Mycobacteria). Univariate analysis showed
that adding these patients to the patients receiving
chronic azithromycin therapy, showed a near-significant
trend towards a lower mortality. We did not exclude
these patients in our cohort as these patients were in aclinically stable state and exclusion of these patients
might give a selected view of the overall NCFB population.
These results suggest that adequate antibiotic treatment
based on underlying infectious cause or adequate use of
long-term macrolide treatment may have an impact on
mortality, but more prospective research is needed to
confirm these findings.
In conclusion, our 5.18-year mortality analysis showed a
mortality rate of 20.4%. Variables associated with an
increased probability of mortality in patients with NCFB
were age, gender, smoking habits, PACC status, increased
total number of different bacterial species in all collected
sputa, spirometric values, radiological severity, extent of
disease and COPD associated NCFB. Multivariate risk factors
associated with lower survival are increasing age, number
of lobes affected and COPD associated NCFB.
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